Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Intel Rejects TSMC’s Allegations of Trade-Secret Leaks as Legal Battle Escalates 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Tunisian Opposition Figure Chaima Issa Arrested Amid Rising Crackdown 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
Dollar Weakens Ahead of Expected Federal Reserve Rate Cut 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
The US Food and Drug Administration (FDA) is planning to regulate the use of the cannabis compound CBD in food and supplements after weighing the evidence on the compound's safety.
The FDA will decide whether regulating legal cannabis will require new agency rules or new legislation from Congress.
Cannabis products, excluding Epidiolex, are illegal at the federal level in the US, although some states allow their use.
According to Patrick Cournoyer, who heads the FDA office developing the agency's cannabis strategy, the FDA will ascertain if CBD can be safely eaten every day for a long period or during pregnancy amid concerns about future fertility.
.
